Buy & Sell Charles River Laboratories Intl. Inc (CRL) – Charles River Laboratories Intl. Inc Price Today
Aura AI Summary
Key Stats
- $8.97BMarket Cap
- HealthSector
- -18.16%3M Drawdown
- $11.32BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 32 daysTypical Hold Time
Charles River Laboratories Intl. Inc (CRL) is currently valued at a market capitalization of $8.97B, with an enterprise value of $11.32B. Over the past 52 weeks, Charles River Laboratories Intl. Inc has traded between a low of $134.98 and a high of $226.77, highlighting its annual price range. Over the past three months, Charles River Laboratories Intl. Inc has recorded a drawdown of -18.16%, reflecting recent price volatility. On average, investors hold Charles River Laboratories Intl. Inc for approximately 32 days, indicating typical investor behavior on the platform.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Most Recent News
CallPhantom scam apps on Google Play fake call logs but charge real money, downloaded 7.3M+ times.
ESET researchers uncovered 28 fraudulent Android apps named CallPhantom on Google Play that falsely claim to provide call logs, SMS, and WhatsApp history for any phone number in exchange for payment. These apps, downloaded over 7.3 million times, gen...
Oculis secures FDA agreement on trial design for Privosegtor in optic neuritis treatment
Oculis Holding AG has received FDA Special Protocol Assessment (SPA) approval for its Phase 3 PIONEER-1 trial of Privosegtor, a novel neuroprotective drug for optic neuritis (ON). This agreement confirms the trial design is suitable to support a futu...
Pakistan’s HBL launches Temenos Core Banking, modernizing 40M accounts across 200 branches.
Habib Bank Limited (HBL) in Pakistan has successfully implemented Temenos Core Banking, marking a major modernization effort. The initial phase migrated accounts from 200 branches, supporting both Conventional and Islamic banking. Once fully deployed...